Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Edgewise Therapeutics Inc (EWTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: EWTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $38.82
1 Year Target Price $38.82
| 5 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 40.01% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.35B USD | Price to earnings Ratio - | 1Y Target Price 38.82 |
Price to earnings Ratio - | 1Y Target Price 38.82 | ||
Volume (30-day avg) 10 | Beta 0.29 | 52 Weeks Range 10.60 - 38.12 | Updated Date 07/2/2025 |
52 Weeks Range 10.60 - 38.12 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.55 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -21.08% | Return on Equity (TTM) -30.29% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 916837833 | Price to Sales(TTM) - |
Enterprise Value 916837833 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.6 | Shares Outstanding 105200000 | Shares Floating 62576247 |
Shares Outstanding 105200000 | Shares Floating 62576247 | ||
Percent Insiders 0.42 | Percent Institutions 104.04 |
Upturn AI SWOT
Edgewise Therapeutics Inc
Company Overview
History and Background
Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for severe, inherited muscle disorders. Founded to address unmet needs in Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD), Edgewise has advanced rapidly through preclinical and clinical development stages.
Core Business Areas
- Muscle Disease Therapeutics: Focuses on the research, development, and commercialization of therapies for Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), and other inherited muscle disorders, targeting underlying causes rather than just symptom management.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientific advisors specializing in neuromuscular diseases. The organizational structure supports efficient preclinical and clinical development, with a strong emphasis on research and development.
Top Products and Market Share
Key Offerings
- EDG-5506: EDG-5506 is an orally administered small molecule designed to address DMD and BMD. It inhibits myosin, thereby reducing muscle damage caused by excessive contraction and relaxation cycles. Currently in Phase 2/3 clinical trials. Market share is currently 0% as the product is not yet approved. Competitors include Sarepta Therapeutics (SRPT), PTC Therapeutics (PTCT), and Solid Biosciences (SLDB).
Market Dynamics
Industry Overview
The neuromuscular disease therapeutics market is experiencing substantial growth driven by advancements in gene therapy, small molecule drugs, and personalized medicine. High unmet medical needs and increasing awareness of rare diseases contribute to market expansion.
Positioning
Edgewise Therapeutics Inc. is positioned as an innovator in the muscle disease therapeutic space, particularly with its focus on small molecule myosin inhibitors. This approach offers a potential advantage over gene therapies and other modalities in terms of accessibility and scalability.
Total Addressable Market (TAM)
The DMD and BMD market is expected to reach billions of dollars annually. Edgewise is positioned to capture a significant share of this market with successful development and commercialization of EDG-5506. Estimated TAM is around $3 billion by 2030.
Upturn SWOT Analysis
Strengths
- Novel Mechanism of Action (Myosin Inhibition)
- Strong Intellectual Property Portfolio
- Experienced Management Team
- Clinical-Stage Asset with Promising Early Data
Weaknesses
- Single Lead Product (EDG-5506)
- High Cash Burn Rate typical of Biotech companies
- Clinical Trial Risks and Regulatory Hurdles
- Reliance on Successful Clinical Trial Outcomes
Opportunities
- Expansion into Additional Muscle Disease Indications
- Potential Partnerships and Collaborations
- Orphan Drug Designation and Regulatory Benefits
- Market Growth in Neuromuscular Disease Therapeutics
Threats
- Competition from Established Pharmaceutical Companies
- Clinical Trial Failures
- Regulatory Delays or Rejection
- Patent Infringement or Invalidity
Competitors and Market Share
Key Competitors
- SRPT
- PTCT
- SLDB
- NSDQ
Competitive Landscape
Edgewise Therapeutics Inc. faces competition from companies with approved therapies and those developing gene therapies. Its small molecule approach offers a potential competitive advantage in terms of accessibility and scalability, but it must demonstrate superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in increased research and development activities and stock appreciation/depreciation based on clinical trial progress.
Future Projections: Future growth depends on successful completion of clinical trials for EDG-5506 and potential expansion into other indications. Analyst estimates vary widely depending on clinical trial success probabilities.
Recent Initiatives: Recent initiatives include ongoing Phase 2/3 clinical trials for EDG-5506, presentations at scientific conferences, and strategic collaborations.
Summary
Edgewise Therapeutics Inc. is a promising clinical-stage company focused on developing therapies for muscle disorders, particularly DMD and BMD. The company's lead product, EDG-5506, has shown potential, but its success hinges on positive clinical trial results and regulatory approval. The company has a strong leadership team and novel MOA, but also faces competition and the high risk inherent in pharmaceutical development, but faces challenges of securing future funding as it is an early stage company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Edgewise Therapeutics Inc. website, SEC Filings, ClinicalTrials.gov, Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Investment decisions should be made in consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Edgewise Therapeutics Inc
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2021-03-26 | President, CEO & Director Dr. Kevin Koch Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 117 | Website https://edgewisetx.com |
Full time employees 117 | Website https://edgewisetx.com | ||
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.